Indian drugmakers Eris Lifesciences, Wockhardt and Lupin are prepping to cash in when Danish company Novo Nordisk bows out of ...

Novo Nordisk to phase out insulin pens and cartridges in India; Eris, Wockhardt and Lupin prepare to capture Rs 600-800 crore ...

Novo Nordisk is one of Europe’s largest companies and a global leader in the treatment of two major lifestyle diseases – ...

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill.

In today's Pharmalittle roundup, we're reading about Novo Nordisk layoffs, an Amgen discount program, and more.

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...

Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...

Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to ...

Weight-loss drugmaker to cut 11.5% of staff 5,000 job cuts in home country of Denmark Expects annual savings of $1.3 billion Will boost performance-based culture, CEO says Shares up 2.1% The ...

Morgan Stanley has downgraded Novo Nordisk, whose U.S. shares are already down a third this year. That downgrade forecasts ...